Table 3.

Multivariate Analysis of Efficacy Endpoints with Baseline Characteristics in Patients Randomly Assigned to Receive Lenvatinib

Baseline efficacy endpoints	p-value	Hazard ratio [CI]
Progression-free survival
ECOG PS (0 vs. 1)	0.0032	0.55 [0.36–0.82]
Sums of target lesions	0.0587	1.00 [1.00–1.01]
NLR	0.0009	1.08 [1.03–1.12]
Age	0.0459	1.02 [1.00–1.04]
Overall survival
ECOG PS (0 vs. 1)	0.0012	0.43 [0.26–0.72]
Sums of target lesions	0.4145	1.00 [1.00–1.01]
NLR	0.0128	1.07 [1.02–1.14]
Age	0.2125	1.02 [0.99–1.04]